We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

COR:NYSECencora, Inc. Analysis

Data as of 2026-05-31 - not real-time

$269.36

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Cencora’s stock is trading at $269.36, essentially flat on its 20‑day SMA of 269.3 but well below the 50‑day (298.7) and 200‑day (326.1) averages, signaling a medium‑term bearish backdrop. The 14‑day RSI sits at 41, indicating the shares are not yet oversold, while the MACD line has crossed above its signal, producing a bullish histogram of +2.6. Volume has been trending lower, which tempers the MACD optimism and suggests waning buying interest. Revenue grew modestly 3.8% YoY to $78.36 B, but gross margin is only 3.8% and operating margin 1.7%, reflecting thin profitability. The company’s PE of 20.7 is below the industry average of 27.6, yet the DCF‑derived fair value of $61 is dramatically lower than the current price, highlighting a valuation disconnect. Free cash flow is negative (‑$318 M) and debt‑to‑equity exceeds 400, raising concerns about financial resilience.
Dividend yield is modest at 0.89% and, despite a low payout ratio of 18%, the sustainability is questionable given cash‑flow constraints. Management announced a $2 B share‑repurchase program and raised FY‑2026 EPS guidance, which provides a short‑term catalyst for price support. However, recent securities‑fraud and class‑action investigations introduce heightened regulatory risk that could impair the stock’s upside. The market’s “Extreme Greed” sentiment (fear‑greed index 94) may be inflating demand despite the underlying fundamentals. Overall, the technical picture is mixed, the fundamentals are weak, and the legal backdrop is uncertain, suggesting caution. Investors should weigh the near‑term support from the buyback against the long‑term challenges of high leverage and thin margins.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near 20‑day SMA indicating short‑term support
  • decreasing volume suggests weakening buying pressure
  • ongoing securities fraud investigation adds downside risk

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • low profit margins and negative free cash flow limit earnings expansion
  • high debt‑to‑equity ratio constrains financial flexibility
  • share repurchase program may buoy price but does not address structural issues

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • persistent low margins and modest revenue growth
  • DCF fair value far below market price
  • elevated regulatory/legal risk and leverage

Key Metrics & Analysis

Financial Health

Revenue Growth3.80%
Profit Margin0.78%
P/E Ratio20.7
ROE107.13%
ROA3.49%
Debt/Equity420.99
P/B Ratio15.4
Op. Cash Flow$2.3B
Free Cash Flow$-318246112
Industry P/E27.6

Technical Analysis

TrendBearish
RSI41.2
Support$244.82
Resistance$310.37
MA 20$269.31
MA 50$298.72
MA 200$326.14
MACDBullish
VolumeDecreasing
Fear & Greed Index94.07

Valuation

Fair Value$61.30
Target Price$356.83
Upside/Downside32.47%
GradeOvervalued
TypeValue
Dividend Yield0.89%

Risk Assessment

Beta-0.00
Volatility60.16%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.